Sramana Mitra: Your primary go-to-market strategy is an OEM strategy? Coby Sella: Yes. Our goal is to deploy as many clients as possible. Our footprint in the industry today is about a quarter of a billion devices using Sansa technology, whether it is Sansa providing platform security capabilities or Sansa delivering embedded software within the trusted
Sramana Mitra: My next question is from an industry point of view. What are the trends and where do you see open problems that are perhaps not in your product roadmap but are things that you are seeing just because of your deep penetration and insight of the space? Where do you see the problems
Sramana Mitra: The numbers you are quoting are amazing. Even in India, you cannot get a great engineer for $25,000. Ander Michelena: You can get very good talent at a cheaper rate. That is one of our main competitive advantages. We are almost more than 300 people in the company at this point. Most of
Sramana Mitra: In that case, the software that you are delivering goes as embedded systems? Coby Sella: Sansa’s solution actually requires implementation of clients. These clients will be embedded within the SOC. We are relying on the SOC’s platform security. This could be a piece of software in a secure environment. For the sake of
Abraham Gutman: Another level of quality analysis that we do is on the meta data in the images. You know how JPEGs have some meta data. It has a little bit of GPS stuff. In a JPEG, you may have a few dozen meta tags, so to speak. In a medical image, you have several
Sramana Mitra: Let’s step back. What I’m trying to trace here is more of a case study of the entrepreneur’s journey. What was the first thing that you did when you launched the company? It sounds like you were able to convince investors. What kind of investors were these? Ander Michelena: The good thing about
Coby Sella: Alternatively, if the management company changes within a certain set of years, this mechanism will be applicable and replace the entity with another one. The solution itself has the flexibility to rely on these devices and to delegate the provisioning technology from one entity to the next one up the chain, which is
Abrahama Gutman: You have to check the sub-assemblies where they are being assembled and put together into a data submission, which occurs typically every six weeks for a period of three to four years. You should also check that the submission meets the requirements of the charter of the clinical trial. It’s important and is typically done after